PARP2 and B-cell non-Hodgkin lymphoma: However, on in vivo models of MYC-driven B-cell lymphoma, Galindo-Campos et al. [82] report different roles for both PARP1 and PARP2 on tumor progression, where PARP1 depletion is associated with increased frequency of T cells, proinflammatory phenotypes and consequent accelerated tumorigenesis, while PARP2 depletion halts B-cell expansion through DNA damage-mediated death.